Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review

Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative

“…Thus, infectious complications after TR-PB represent an important challenge for the urologist and for patients. On the other hand, several authors reported that fosfomycin trometamol (FT) could be a valid alternative for antibiotic prophylaxis of TR-PB due to its low profile of resistance, elevated activity against multidrug-resistant (MDR) Gram-negative bacteria and favorable pharmacokinetic properties [8][9][10]. Here, we aimed to compare the clinical outcome of patients who underwent TR-PB and received prophylaxis with either FT or ciprofloxacin (CIP), by means of a retrospective, comparative cohort study.…”

Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012

“…Based on in vitro data and PK/PD modelling, a high dose and prolonged infusion combination strategy has been suggested [40]. Clinically, doses of 4 g four times daily and up to 8 g three times daily have been reported [41,42], but appropriate dosage regimens in XDR situations have not yet been established.…”

“…As the i.v. form of fosfomycin is not approved in many countries, most experience is with oral preparations of the agent [42]. This achieves high concentrations in the urinary tract and has been used in the treatment of XDR and even PDR UTIs.…”

A validated method for the quantification of fosfomycin on dried plasma spots by HPLC–MS/MS: Application to a pilot pharmacokinetic study in humans

“…Fosfomycin is generating substantial interest as an intravenous or enteral therapy for multidrug resistant (MDR) pathogens [3,4]. With an increasing prevalence of MDR bacteria, combined with a steadily decreasing number of usable antibiotics available, fosfomycin offers a potential infection treatment option for critically-ill patients.…”